About this trial
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.
The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.
The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
Eligibility criteria
Qualifiers
Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.
Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
Affiliation to a social security scheme
Disqualifiers
Minor patient
Pregnant patient
Patient under guardianship or conservatorship
Patients who object to the collection of their medical/paramedical data
Trial design
Treatments tested in this trial
- molecular analysis